Satellos Bioscience Inc. (MSCL.V)
| Previous Close | 0.4000 |
| Open | 0.4050 |
| Bid | 0.3800 x N/A |
| Ask | 0.3900 x N/A |
| Day's Range | 0.3900 - 0.4250 |
| 52 Week Range | 0.2200 - 1.2000 |
| Volume | |
| Avg. Volume | 39,291 |
| Market Cap | 16.301M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
Satellos Bioscience Announces Significant Increase in Muscle Size and Function in Duchenne Muscular Dystrophy Disease Model
- 40% increase in muscle size compared to control mice - 25% increase in muscle force, approaching levels seen in normal miceToronto, Ontario--(Newsfile Corp. - February 6, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce results from multiple preclinical studies in
- Newsfile
Satellos Bioscience Announces Development Candidate
- SAT-3153 Designated for pre-IND Studies - Toronto, Ontario--(Newsfile Corp. - January 3, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce that it has designated SAT-3153 for development towards an IND filing."We are thrilled to be in a position to move SAT-3153 ..
- Newsfile
Satellos Bioscience Announces Q3 2022 Financial Results and Operational Highlights
Toronto, Ontario--(Newsfile Corp. - November 23, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a drug discovery company developing therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today its financial results and operational highlights for the quarter ending September 30, 2022. The Company's interim condensed consolidated financial statements for the quarter ended September 30, 2022, a
